Partnership9 Dec 2025, 05:41 pm
Zydus Lifesciences and Formycon Partner for Biosimilar to Keytruda in US, Canada
AI Summary
Zydus Lifesciences Ltd, through its subsidiary, has entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of a biosimilar to Keytruda® (Pembrolizumab) in the USA and Canada markets. Formycon will develop, register, manufacture and supply the product, while Zydus will be responsible for the commercialization. The BLA application is expected to be submitted to the USFDA soon.
Key Highlights
- Zydus Lifesciences and Formycon enter into an exclusive partnership for the licensing and supply of a biosimilar to Keytruda in the US and Canada.
- Formycon will develop, register, manufacture and supply the biosimilar, while Zydus will be responsible for the commercialization.
- The partnership marks Zydus’ entry into the North American biosimilar market.
- The BLA application is expected to be submitted to the USFDA in the near future.
- The partnership aims to make immunotherapy affordable and accessible to patients in need.